Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ: RXRX · Real-Time Price · USD

3.380

+0.050 (1.50%)

At close: Sep 2, 2026, 4:00 PM EDT

3.380

0.00 (0.00%)

Pre-market: Sep 3, 2026, 4:08 AM EDT

Recursion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	545.68	743.29	594.35	391.57	549.91	285.12
Short-Term Investments	-	-	-	-	-	231.45
Cash & Short-Term Investments	545.68	743.29	594.35	391.57	549.91	516.56
Cash Growth	3.92%	25.06%	51.79%	-28.79%	6.46%	97.07%
Accounts Receivable	-	-	-	-	-	0.03
Other Receivables	14.39	24.65	49.17	3.09	2.75	9.06
Receivables	14.39	24.65	49.17	3.09	2.75	9.09
Prepaid Expenses	8.68	11.74	29.6	-	-	-
Restricted Cash	5.39	4.59	3.05	3.23	1.28	1.55
Other Current Assets	29.32	28.57	38.11	40.25	15.87	7.51
Total Current Assets	603.46	812.85	714.27	438.14	569.81	534.72
Property, Plant & Equipment	147.07	169.48	233.21	120.17	121.45	64.73
Long-Term Investments	-	4.4	-	-	-	-
Goodwill	160.35	162.16	148.87	52.06	0.8	0.8
Other Intangible Assets	282.89	309.9	335.86	36.44	1.31	1.39
Long-Term Deferred Tax Assets	0.96	0.96	1.93	-	-	-
Other Long-Term Assets	17.94	14.39	14.45	6.89	7.92	8.72
Total Assets	1,213	1,474	1,449	653.7	701.29	610.35

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	12.67	18.12	21.61	3.95	4.59	2.82
Accrued Expenses	54.86	69.53	80.28	41.76	30.29	27.67
Current Portion of Long-Term Debt	9.44	0.12	0.11	0.04	0.1	0.09
Current Portion of Leases	13.25	21.63	22.11	6.12	5.95	-
Current Unearned Revenue	29.5	37.61	61.77	36.43	56.73	10
Other Current Liabilities	0.17	0.7	1.59	4.87	2.62	6.08
Total Current Liabilities	119.89	147.71	187.47	93.17	100.27	46.66
Long-Term Debt	4.75	0.19	0.68	1.1	0.54	0.63
Long-Term Leases	39.19	56.02	85.59	43.41	44.42	-
Long-Term Unearned Revenue	112.82	114.01	118.77	51.24	70.26	6.67
Long-Term Deferred Tax Liabilities	18.31	23.26	16.58	1.34	-	-
Other Long-Term Liabilities	2.7	2.08	4.73	-	-	13.45
Total Liabilities	297.67	343.27	413.82	190.26	215.48	67.41

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0.01	0	0	0	0
Additional Paid-In Capital	3,212	3,170	2,474	1,431	1,125	943.14
Retained Earnings	-2,325	-2,076	-1,431	-967.62	-639.56	-400.08
Comprehensive Income & Other	27.99	36.72	-7.64	-	-	-0.13
Total Common Equity	915	1,131	1,035	463.44	485.81	542.94
Shareholders' Equity	915	1,131	1,035	463.44	485.81	542.94
Total Liabilities & Equity	1,213	1,474	1,449	653.7	701.29	610.35

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	66.64	77.97	108.49	50.67	51.01	0.72
Net Cash (Debt)	479.05	665.33	485.86	340.89	498.91	515.84
Net Cash Growth	9.61%	36.94%	42.52%	-31.67%	-3.28%	106.63%
Net Cash Per Share	0.94	1.49	1.77	1.64	2.84	4.12
Filing Date Shares Outstanding	535.34	527.4	401.99	234.65	191.23	170.77
Total Common Shares Outstanding	535.05	528.18	396.8	234.27	191.02	170.27
Working Capital	483.58	665.14	526.8	344.97	469.55	488.06
Book Value Per Share	1.71	2.14	2.61	1.98	2.54	3.19
Tangible Book Value	471.77	658.8	550.05	374.94	483.7	540.75
Tangible Book Value Per Share	0.88	1.25	1.39	1.60	2.53	3.18
Machinery	-	121.86	128.29	82.22	67.69	53.08
Construction In Progress	-	0.51	2.71	3.23	8.75	16.45
Leasehold Improvements	-	70.78	72.73	45.93	41.87	13.94

SEC Filings: 10-K · 10-Q